![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2006, The American Society for Cell Biology Phosphoinositide 3-Kinase Activity Controls the Chemoattractant-mediated Activation and Adaptation of Adenylyl Cyclase ![]() * Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4256 † Pharmacology Research Associate Training Fellowship Program, National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MD 20892-6200 John York, Monitoring Editor Address correspondence to: Carole A. Parent (parentc/at/helix.nih.gov). Received August 19, 2005; Accepted October 21, 2005. This article has been cited by other articles in PMC.Abstract The binding of chemoattractants to cognate G protein-coupled receptors activates a variety of signaling cascades that provide spatial and temporal cues required for chemotaxis. When subjected to uniform stimulation, these responses are transient, showing an initial peak of activation followed by a period of adaptation, in which activity subsides even in the presence of stimulus. A tightly regulated balance between receptor-mediated stimulatory and inhibitory pathways controls the kinetics of activation and subsequent adaptation. In Dictyostelium, the adenylyl cyclase expressed during aggregation (ACA), which synthesizes the chemoattractant cAMP, is essential to relay the signal to neighboring cells. Here, we report that cells lacking phosphoinositide 3-kinase (PI3K) activity are deficient in signal relay. In LY294002-treated cells, this defect is because of a loss of ACA activation. In contrast, in cells lacking PI3K1 and PI3K2, the signal relay defect is because of a loss of ACA adaptation. We propose that the residual low level of 3-phosphoinositides in pi3k1-/2- cells is sufficient to generate the initial peak of ACA activity, yet is insufficient to sustain the inhibitory phase required for its adaptation. Thus, PI3K activity is poised to regulate both ACA activation and adaptation, thereby providing a link to ensure the proper balance of counteracting signals required to maintain optimal chemoresponsiveness. INTRODUCTION Chemotaxis is a fundamental process in which cells migrate directionally by sensing and responding to extracellular gradients of chemoattractants. This process is exhibited in a variety of biological responses, including wound healing, angiogenesis, and embryogenesis as well as during the recruitment of neutrophils to sites of inflammation. Chemotaxis is also essential for the survival of the social amoebae Dictyostelium discoideum. Neutrophils and Dictyostelium cells migrate using amoeboid movements, characterized by leading edge pseudopod extensions and back retractions/contractions (Chung et al., 2001 ; Iijima et al., 2002 ; Weiner, 2002 ; Parent, 2004 ). It has been determined that these cells are extremely sensitive and can detect spatial gradients in which the chemoattractant concentration differs by as little as 1% between the front and the back of the cell (Mato et al., 1975 ; Zigmond, 1977 ). Furthermore, these cells are responsive over a wide dynamic range of chemoattractant concentrations, which can vary over at least 4 orders of magnitude. This dynamic responsiveness requires a tightly regulated balance between stimulatory and inhibitory responses, which are both initiated upon chemoattractant receptor activation (Zigmond and Sullivan, 1979 ; Dinauer et al., 1980a ,b ). Temporal modulation of stimulatory and inhibitory inputs give rise to transient responses composed of an initial peak of activation followed by a period of adaptation, during which the system is refractory to further signals, and finally deadaptation, which resets the system and allows cells to respond to additional chemotactic signals (Parent and Devreotes, 1999 ; Devreotes and Janetopoulos, 2003 ). Intriguingly, although the mechanisms that control the activation process have been extensively characterized, most of the adaptive mechanisms remain poorly understood.For neutrophils and Dictyostelium, the binding of chemoattractants to G protein-coupled receptors stimulates a variety of responses, including an increase in the levels of cAMP (Harvath et al., 1991 ; Dai et al., 1994 ; Saran et al., 2002 ). In Dictyostelium, the signaling pathways that lead to the activation of the adenylyl cyclase expressed during aggregation (ACA), which converts ATP into cAMP, have been extensively studied (Kriebel and Parent, 2004 ). In this organism, cAMP acts as a chemoattractant by binding to specific seven-transmembrane cAMP receptors, cARs. Stimulation of the receptors leads to the activation of ACA and the synthesis of more cAMP, a fraction of which is secreted to initiate a signal relay loop that propagates the signal to neighboring cells. As chemotaxis proceeds, Dictyostelium cells begin to migrate in a head-to-tail manner, generating long streams of cells (Pitt et al., 1992 ; Kriebel et al., 2003 ). We have previously shown that this streaming process not only depends on the presence of ACA itself but also on its cellular distribution to the rear of cells (Kriebel et al., 2003 ). We propose that the spatial restriction of ACA provides a compartment from which cAMP is secreted, thereby locally attracting neighboring cells.The activation of ACA shows an absolute requirement for the pleckstrin homology (PH) domain-containing protein cytosolic regulator of adenylyl cyclase (CRAC) (Insall et al., 1994 ; Lilly and Devreotes, 1995 ). On receptor stimulation, Gβγ subunits activate phosphoinositide 3-kinase (PI3K) in a Ras-dependent manner, leading to the production of 3-phosphoinositides (3-PI) to which CRAC binds via its PH domain (Funamoto et al., 2002 ; Comer et al., 2005 ). After the addition of a uniform dose of chemoattractant, CRAC is rapidly and transiently recruited to the plasma membrane around the entire periphery of the cell. In contrast, when cells are exposed to a gradient of chemoattractant, the membrane recruitment is restricted to the side of the cell facing the highest concentration of attractant (Parent et al., 1998 ). This dynamic distribution is part of an elegant mechanism that cells use to compartmentalize signal transduction events. In both neutrophils and Dictyostelium, PI3K signaling has been shown to localize to the leading edge of chemotaxing cells, whereas the enzyme that degrades the products of PI3K, the tumor suppressor PTEN, localizes to the back and sides (Servant et al., 2000 ; Funamoto et al., 2002 ; Iijima and Devreotes, 2002 ; Li et al., 2005 ). Disruption of the balance between these two enzyme activities, either by pharmacological inhibition or targeted gene disruption, results in defects in cell polarity, spatial actin organization, gradient sensing, and efficiency of chemotaxis (Chung et al., 2001 ; Iijima et al., 2002 ; Stephens et al., 2002 ). Although the mechanism by which CRAC activates ACA remains to be determined, recent findings have shown that the PI3K-mediated activation of CRAC independently regulates ACA activation and chemotaxis, suggesting that these two processes are subject to coordinated regulation (Comer et al., 2005 ).Interestingly, the activation of ACA requires another cytosolic regulator called Pianissimo (Pia) (Chen et al., 1997 ). In contrast to CRAC, Pia harbors no known protein motifs, but several Pia homologues in organisms that range from yeast to mammals have been identified. The mammalian Pia homologue, called Rictor or mAVO3, is part of the target of rapamycin (TOR) complex 2 (TORC2), along with TOR and LST8, and has been shown to regulate cytoskeletal rearrangements (Sarbassov et al., 2004 ). We have recently shown that in Dictyostelium the components of TORC2, which also include the AVO1 homologue ras interacting protein 3 (RIP3), function together in a preformed complex to regulate ACA activity (Lee et al., 1999 , 2005 ). Moreover, reconstitution experiments established that TORC2 can form in the absence of CRAC. Given previous data showing that ACA activity can be reconstituted in lysates derived from cells lacking both Pia and CRAC only when both proteins are added back (Chen et al., 1997 ), these findings suggest that ACA activation requires an input from both TORC2 and CRAC.In this article, we show that PI3K is central to both activation and adaptation of ACA in response to chemoattractant stimulation. Our results are consistent with a model in which PI3K coordinately regulates pathways that control chemotaxis, ACA activation, and ACA adaptation. Control of all three pathways by PI3K provides an efficient mechanism for a strict regulation and ensures the proper balance of these counteracting inputs on ACA activation. MATERIALS AND METHODS Reagents All chemicals were purchased from Sigma Chemical (St. Louis, MO) or VWR (West Chester, PA), unless otherwise indicated. Monoclonal anti-green fluorescent protein (GFP) antibody was purchased from Covance Research Products (Berkeley, CA). Enhanced chemiluminescence detection reagent and the cAMP radioimmunoassay kit were purchased from GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). Micropipettes for chemotaxis assays were from Eppendorf (Hamburg, Germany). [α-32P]ATP (800 Ci/mmol) was purchased from MP Biomedicals (Irvine, CA). Precast NuPage Bis-Tris protein electrophoresis gradient gels were purchased from Invitrogen (Carlsbad, CA). Cell Lines The wild-type Ax3 and pten-/pi3k1-/2- cell lines (Janetopoulos et al., 2005 ) were a kind gift from Peter Devreotes (Johns Hopkins University School of Medicine, Baltimore, MD). The pi3k1-/2- (Zhou et al., 1995 ; Buczynski et al., 1997 ) and PI3K2/pi3k1-/2- (Funamoto et al., 2002 ) cell lines were a kind gift from Rick Firtel (University of California, San Diego, San Diego, CA).Cell Growth and Differentiation Cells were cultured in shaking suspension in HL5 medium and differentiated to the chemotaxis competent aggregation stage essentially as described previously (Devreotes et al., 1987 ; Parent et al., 1998 ). In brief, cells from log phase suspension culture were harvested and differentiated for 4.5-7 h in suspension at 2 × 107 cells/ml in development buffer (DB; 5 mM sodium phosphate buffer, pH 6.2, 2 mM MgSO4, and 0.2 mM CaCl2) with exogenous pulses of 75 nM cAMP every 6 min. To verify that cells differentiated to the chemotaxis competent stage, we performed Western blot analysis of the early developmental markers, chemoattractant receptor (cAR1), and the aggregation stage adenylyl cyclase (ACA).Microscopy For the micropipette chemotaxis assay and CRAC translocation assay, cells were viewed with an inverted Zeiss Axiovert 200 microscope (Carl Zeiss, Thornwood, NY) equipped with automated filter wheels (Ludl Electronic Products, Hawthorne, NJ). Images were recorded with a CoolSnap HQ charge-coupled device camera (Roper Scientific, Trenton, NJ) operated by IPLab software (Scanalytics, Fairfax, VA). All images in a series were processed identically using IPLab and/or Adobe Photoshop. Fluorescent images were viewed with the appropriate filter set and nonfluorescent cells were viewed using either Varel or differential interference contrast optics. Chemotaxis Assays To analyze the migration of groups of individual cells, the micropipette chemotaxis assay was carried out essentially as described previously (Parent et al., 1998 ). In this assay, cells undergo starvation induced differentiation to the chemotaxis competent aggregation stage (4-7 h), and their directed migration is observed in a gradient supplied by a micropipette filled with the chemoattractant cAMP at a concentration of 10 μM. The chemotaxis was recorded with a 15-s interval between successive frames. Chemotaxis of a large population of cells was observed with the under agarose assay, as described previously (Nelson et al., 1975 ; Comer et al., 2005 ). Briefly, 3-4 ml of 0.5% agarose in DB containing 1 mM caffeine was poured into 35-mm Petri dishes. The agarose was allowed to cool completely, and then three equidistant wells were cut out of the agarose with a wide-bore Pasteur pipet. The middle well was filled with 1 μM cAMP in DB, and the gradient was allowed to establish for 30 min before plating cells. Differentiated cells were suspended at 2 × 107 cells/ml in DB containing 2 mM caffeine and plated into the outer wells. After the cells were allowed to chemotax for ~1 h, the wells were carefully overlaid with phosphate buffer and visualized on a Leica stereoscope. Each assay was performed in triplicate, and the results are representative of at least three independent experiments on different days, and wild-type cells were always assayed along with the tester cell line.CRAC Translocation Assay The chemoattractant-mediated recruitment of CRAC (CRAC-GFP) to the plasma membrane was observed on a fluorescence microscope as described previously (Parent et al., 1998 ). Briefly, CRAC-GFP-expressing cells were stimulated with 20 μM cAMP and fixed (1% formaldehyde, 0.125% glutaral-dehyde, and 0.01% Triton X-100 in phosphate buffer) after 5 s of stimulation. Cells were viewed as described above.Adenylyl Cyclase and cAMP Accumulation Assays Activation of adenylyl cyclase via chemoattractant receptor stimulation was measured essentially as described previously (Parent and Devreotes, 1995 ; Parent et al., 1998 ). Briefly, differentiated cells were stimulated with 50 μM cAMP and filter lysed at the indicated time points into Tris buffer containing [α-32P]ATP diluted with unlabeled ATP to a final concentration of ~150 Ci/mol. The reaction was allowed to proceed for 1 min, stopped with SDS/ATP, and the radiolabeled cAMP was purified by sequential Dowex-AG 50W X-4 and alumina column chromatography (Salomon, 1979 ). Adenylyl cyclase measurements by this assay exhibit considerable variation from experiment to experiment. Although the relative extent of activation of different cell lines or treatment conditions is highly reproducible between experiments, the absolute activity can vary significantly (2- to 3-fold at times) from day to day. Therefore we, and others in the field, have chosen to present adenylyl cyclase activation data as representative of results from at least three to five or more independent experiments, each performed in duplicate on a given day. Furthermore, comparisons between different cell lines or treatment conditions are made on samples assayed on the same day, using the same reagent mixture.To measure activation of adenylyl cyclase by global stimulation of both heterotrimeric G proteins and small GTPases, lysates were incubated with 100 μM guanosine 5′-O-(3-thio)triphosphate (GTPγS) and, after 5 min, aliquots of the lysate were assayed for adenylyl cyclase activity for 2 min. For the mixing experiments, cell lines were mixed, lysed together, and otherwise assayed exactly as described above. To prepare cytosolic and membrane extracts for the in vitro complementation experiment, cells were suspended at 8 × 107 cells/ml in simple lysis buffer (SLB; 10 mM Tris, pH 7.5, 0.2 mM EGTA, and 200 mM sucrose), filter lysed, and centrifuged at 9500 × g for 20 min. The supernatant fraction was denoted the cytosolic extract and was used without further dilution. The pellet fraction was resuspended in an equivalent volume of SLB and designated the membrane fraction. The in vitro complementation was performed in essentially the same manner as the direct GTPγS-stimulated adenylyl cyclase activation assay, except that cells were lysed directly into a tube on ice containing the cytosolic or membrane extract, as indicated. After 5 min, the adenylyl cyclase activity of the mixture was assayed for 2 min, as described. Chemoattractant-mediated cAMP production was measured in differentiated cells after the addition of 5 μM 2′deoxy-cAMP in the presence of 10 mM DTT and 200 μM 3-isobutyl-1-methylxanthine using the cAMP radioimmunoassay kit from GE Healthcare. RESULTS Disruption of PI3K Activity Impairs Streaming In previous work examining the role of 3-PIs in CRAC function, we introduced a point mutation in the predicted 3-PI binding motif within the CRAC PH domain (R42C-CRAC) and found that this mutant does not support chemotaxis and shows minimal ACA activation (Comer et al., 2005 ). To gain insight into this finding, we more carefully investigated the role of PI3K action in these processes. Although there are six PI3K isoforms in Dictyostelium (Janetopoulos et al., 2005 ), most of the chemoattractant-mediated PI3K activity arises from PI3K1 and PI3K2 (Huang et al., 2003 ). We therefore used cells in which the PI3K1 and PI3K2 isoforms have been disrupted (pi3k1-/2-) for our studies (Zhou et al., 1995 ; Buczynski et al., 1997 ). When we plated pi3k1-/2- cells on nonnutrient agar, we observed that these cells aggregate and differentiate, but they make misshapen terminal differentiation structures, as described previously (Zhou et al., 1995 ). To study this phenotype further, we recorded the differentiation process and found that the normal oscillatory pattern of periodic waves present in wild-type cells is disrupted in pi3k1-/2- cells. Although wild-type cells display regular wave patterns, which arise as cells respond to passing waves of synchronized chemoattractant release from cells in an aggregation center (Parent and Devreotes, 1996 ; Sawai et al., 2005 ), the wave patterns of the pi3k1-/2- cells are irregular and do not propagate far from the aggregation center (our unpublished data). To determine whether this defect is simply caused from aberrant expression of key signaling components, we assessed the expression of the chemoattractant receptor, cAR1, and ACA in pi3k1-/2- cells and found that they were comparable with wild-type cells (Figure 1A ). We found that cAMP-induced cAR1 phosphorylation is normal in pi3k1-/2- cells (Figure 1B
To further assess the developmental defect of the pi3k1-/2- cells, we more carefully examined the chemotactic behavior of pi3k1-/2- cells and found that they failed to align in a head-to-tail manner during chemotaxis, as suggested by Zhou et al. (1998 ). Figure 1C ), a behavior that is more pronounced in cells that are differentiated for 4-5 h (our unpublished data). To observe a larger population of cells, we examined the behavior of pi3k1-/2- cells in the under agarose chemotaxis assay (Nelson et al., 1975 ; Comer et al., 2005 ). Again, we found that, in contrast to wild-type cells, pi3k1-/2- cells do not align and migrate as a diffuse halo of individual chemotaxing cells (Figure 1D
Disruption of PI3K Activity Impairs PH Domain Translocation We previously demonstrated that R42C-CRAC fails to translocate to the plasma membrane upon chemoattractant stimulation and does not support chemotaxis, suggesting that PI3K action, mediated via CRAC translocation, is necessary for chemotaxis (Comer et al., 2005 ). Nevertheless, pi3k1-/2- cells and LY294002-treated wild-type Ax3 cells can still undergo chemotaxis, albeit with reduced polarity and directionality (Figures (Figures1C1C ). Thus, we next examined whether chemoattractant-mediated translocation of CRAC to the plasma membrane is impaired in pi3k1-/2- cells or in LY294002-treated wild-type cells. We observed that, as for other PH domain-containing proteins (Meili et al., 1999 ; Servant et al., 2000 ; Funamoto et al., 2001 ), the recruitment of CRAC-GFP to the membrane is undetectable in pi3k1-/2- cells, whether observed microscopically (Figure 3A ), whereas chemoattractant-induced PI(3,4,5)P3 production is reduced to ~4% that of wild-type cells (Huang et al., 2003 ). Likewise, although Akt/PKB activation is greatly reduced in pi3k1-/2- cells, it is not abolished (Meili et al., 1999 ). Because chemotaxis is very sensitive, we propose that this residual PI3K response is sufficient to promote low levels of CRAC translocation, which are undetectable by our assay, but sufficient to drive the highly sensitive process of gradient sensing and chemotaxis. One consequence of this hypothesis is that there is likely to be signal amplification downstream of CRAC translocation. Thus, cells can recover from the low levels of PI3K-mediated CRAC translocation in pi3k1-/2- cells and upon LY294002 treatment because signal amplification renders cells resilient to significant perturbations in the chemotaxis signaling machinery.
PI3K Regulates Adenylyl Cyclase Activation and Adaptation, but Not Its Cellular Distribution Although ACA is properly expressed in pi3k1-/2- cells, we reasoned that the streaming defect of these cells may arise by a defect in regulating its activity or its cellular distribution. Indeed, we demonstrated previously that cells lacking ACA are unable to stream, although they can sense and migrate directionally toward a point source of cAMP (Pitt et al., 1992 ; Kriebel et al., 2003 ). We also established that ACA is highly enriched at the back of polarized, chemotaxing cells (Kriebel et al., 2003 ) and proposed that this provides a spatially restricted compartment from which cAMP is locally secreted to specifically attract neighboring cells, thus comprising a primary mechanism for signal relay and streaming. To determine whether the streaming defect of PI3K-deficient cells is caused by mislocalization of ACA, we examined its cellular distribution in pi3k1-/2- cells. For these experiments, we expressed ACA-YFP in pi3k1-/2- cells (ACA-YFP/pi3k1-/2-) or treated aca- cells expressing ACA-YFP (ACA-YFP/aca-) with LY294002. We found that, in both cases, ACA-YFP is properly enriched at the back of migrating cells (Figure 4, A and B
We next assessed the activity of ACA in PI3K-deficient cells. For these experiments, we used an activation trap assay, in which cells are stimulated with chemoattractant and at a specific time, rapidly lysed and assayed for adenylyl cyclase activity. When we examined receptor-mediated activation of ACA in pi3k1-/2- cells, we found that they exhibited a dramatic defect in adaptation of the response (Figure 4C ). These findings show that PI3K activity controls the adaptation phase of the chemoattractant-mediated activation of ACA.To further study the balance between 3-PI production and degradation in chemoattractant signaling to ACA, we examined the ACA response in cells deficient in both PI3K and PTEN activity. Deletion of the 3-PI-degrading enzyme PTEN in the pi3k1-/2- background results in cells that have an elevated basal level of CRAC at the plasma membrane, but they do not recruit more CRAC upon chemoattractant stimulation (Janetopoulos et al., 2005 ). These data suggest that, despite elevated basal levels of 3-PIs and membrane-associated CRAC, these cells do not exhibit proper temporal and spatial regulation of 3-PIs upon chemoattractant stimulation. We found that chemoattractant stimulation of these cells gives rise to a normal peak of ACA activation and a partial rescue of the adaptation defect observed in pi3k1-/2- cells (Figure 4D ), our previous observation that crac- cells expressing a point mutation in the 3-PI binding motif within the CRAC PH domain are strongly impaired in their ability to activate ACA supports a direct role for PI3K. From these results, we infer that the loss of streaming during chemotaxis of wild-type cells treated with LY294002 is likely the result of too little ACA activity, as in the streaming defect reported previously for aca- cells (Kriebel et al., 2003 ). We propose that the streaming defect in the pi3k1-/2- cells, in contrast, is because of misregulation of the adaptation response, resulting in locally high concentrations of chemoattractant, which neighboring cells are unable to integrate into a proper streaming response. This hypothesis is further supported by our finding that net cAMP production is dramatically increased in pi3k1-/2- cells and significantly reduced in LY294002-treated wild-type cells (Figure 4FDistinct G Protein-mediated Pathways Control Chemoattractant Signaling Another means of activating ACA is by direct G protein stimulation of cell lysates with the nonhydrolyzable GTP analogue GTPγS, which simultaneously activates the entire cellular complement of GTP binding proteins, both heterotrimeric G proteins and small GTPases. In wild-type cells, GTPγS stimulation results in a net activation of ACA, as observed previously (Figure 5A ). Finally, we again found that reexpression of PI3K2 in the pi3k1-/2- cells restores GTPγS-mediated ACA activation (Figure 5C
DISCUSSION Sensory adaptation was recognized many years ago as important for chemoresponsiveness of both Dictyostelium cells (Devreotes and Steck, 1979 ) and mammalian leukocytes (Zigmond and Sullivan, 1979 ). Selective adaptation seems to be important for neutrophils to integrate conflicting chemotactic signals in a complex environment of multiple chemat-tractants (Foxman et al., 1999 ) and is important for both chemotaxis and signal relay in Dictyostelium (Devreotes and Steck, 1979 ; Van Haastert, 1983 ). However, although Gα9 has recently been identified as a general modulator of inhibitory chemotactic responses (Brzostowski et al., 2004 ), the mechanisms that regulate adaptation remain largely unknown. Progress in this area has undoubtedly been hampered by the complexity of the chemoattractant signaling system. Moreover, the phenotype of Dictyostelium adaptation mutants may be subtle and difficult to identify in a mutagenesis screen. For example, the pi3k1-/2- cells, in spite of their profound ACA adaptation defect, develop relatively normal terminal differentiation structures (Zhou et al., 1995 ).Two opposing receptor-mediated biochemical processes—an excitatory and an inhibitory response—have been proposed to mediate the transient nature of the ACA response (Parent and Devreotes, 1999 ). When both responses reach a steady state, ACA activity returns to basal levels. We present evidence that supports a role for PI3K in both the excitation and inhibition pathways that control ACA in response to chemoattractant stimulation. Analysis of the chemoattractant receptor-mediated ACA activation in pi3k1-/2- cells reveals a profound adaptation defect, implying a key role for PI3K in the mechanism of adaptation. Our finding that deletion of PTEN in the pi3k1-/2- background, which elevates basal 3-PI levels, partially suppresses the adaptation defect suggests a direct role for 3-PIs in this process. In contrast, treatment of wild-type cells with a PI3K inhibitor or expressing a mutant of CRAC that has lost the capacity to bind to 3-PIs in crac- cells drastically reduces activation of the ACA response, pointing to an essential role for 3-PIs in ACA activation. These results are consistent with a model in which PI3K controls both the excitation and the inhibition of the ACA response through independent pathways (see model, Figure 6
We envision four nonmutually exclusive mechanisms for coordinating the output from PI3K signaling to the excitation and inhibition pathways controlling ACA. The first possibility is that the excitation branch is more sensitive than the inhibition branch. Thus, because the inhibition branch would require a greater input from PI3K, inhibition would be more affected than excitation in conditions of reduced PI3K activity and a loss of the adaptation response would occur before the activation is affected. Indeed, the chemoattractant-induced PI(3,4,5)P3 production in pi3k1-/2- cells is greatly reduced compared with wild-type cells, yet pi3k1-/2- cells show a robust initial peak of ACA activation. The second possibility is that the two branches have distinct kinetics, and the temporal delay in the inhibition pathway is exaggerated in the pi3k1-/2- cells. Third, PI3K isoforms other than PI3K1 and PI3K2 could be responsible for the initial activation peak, whereas these two predominant isoforms would specifically control the inhibition branch. Finally, because PI3Ks are known to exhibit both lipid and protein kinase activities (Carpenter et al., 1993 ; Dhand et al., 1994 ; Naga Prasad et al., 2005 ), it is possible that the inhibition pathway leading to ACA adaptation depends on the protein kinase activity of PI3K, which could be regulated independently of the lipid kinase activity. At the moment, it is not known whether the Dictyostelium PI3Ks display protein kinase activity.Our finding that stimulation of cell lysates with GTPγS does not promote ACA activation in pi3k1-/2- cells provides further insight into the mechanisms controlling the adaptive response. Our data are consistent with at least two hypotheses. First, it is possible that pleiotropic defects in the pi3k1-/2- cells impair the GTPγS-mediated activation of ACA, despite the ability of these cells to activate ACA through the G protein-coupled chemoattractant receptor. Alternatively, our results may suggest the presence of a small GTPase that functions downstream of PI3K to attenuate the ACA activation response. This putative GTPase would need to be kinetically slower and/or less sensitive than the receptor-coupled heterotrimeric G protein and the Ras GTPase that has been proposed to activate PI3K (Funamoto et al., 2002 ; Sasaki et al., 2004 ). Thus, in wild-type cells, activation of the upstream Gβγ and Ras would dominate with a net activation of ACA upon GTPγS stimulation. In contrast, in the pi3k1-/2- cells, the efficiency of the Gβγ and Ras signals is reduced because of the low PI3K activity in the excitation branch, and thus, a GTPase functioning in the inhibition branch dominates, resulting in a shift of the balance between excitation and inhibition, thus yielding little or no net activation. The identification of the GTPase and its associated regulators as mediators of ACA inhibition presents a considerable challenge. In Dictyostelium, there are at least six Ras proteins, some with redundant functions, and greater than 20 Ras guanine nucleotide exchange factors (Wilkins and Insall, 2001 ; Kae et al., 2004 ; Wilkins et al., 2005 ). Nevertheless, as these challenges are met, elucidation of the mechanisms of adaptation will provide fundamental insight into chemotaxis and the integration of chemoattractant signal transduction responses.Reduction of PI3K activity affects multiple chemoattractant-mediated processes, pointing to a central role for PI3Ks in the integration of chemoattractant signaling. Previous studies have shown that pi3k1-/2- Dictyostelium cells and neutrophils from PI3Kγ-null mice have reduced directionality, polarity and speed, but chemotaxis can still occur (Hirsch et al., 2000 ; Li et al., 2000 ; Chung et al., 2001 ; Funamoto et al., 2001 ; Iijima et al., 2002 ; Stephens et al., 2002 ; Weiner, 2002 ). Similar effects on chemotaxis were obtained upon PI3K inhibition with LY294002 or wortmannin (Funamoto et al., 2001 ; Wang et al., 2002 ). These observations are consistent with our hypothesis that, in addition to the upstream actin-dependent signal amplification loops that lead to the polarization of PI3K activity (Weiner et al., 2002 ), further downstream amplification of the PI3K response is likely to occur, such that even small PI3K inputs can be amplified into functional responses. This exquisite regulation may help explain the wide dynamic range of chemotactic responsiveness of Dictyostelium. These cells not only migrate directionally in very shallow gradients supplied by a source of 10-9 M cAMP (Mato and Konijn, 1975 ), they can also chemotax in a gradient applied over a constant background concentration of 10-5 M cAMP (Van Haastert, 1983 ). It therefore seems that PI3Ks are involved in regulating multiple effectors of chemoattractant signaling and that these effectors display distinct sensitivities to PI3K products.Our findings suggest a novel mechanism by which PI3K activity regulates the excitation and inhibition pathways that control ACA in response to chemoattractant stimulation. We propose that such a mechanism, in which activation and adaptation are controlled by the same input, allows for a stringent regulation of the excitation/inhibition cycle. By linking two opposing responses, inhibition and excitation responses would always be proportional, ensuring the proper balance that is required to maintain the oscillatory circuit of chemoresponsiveness. We envision that similar coordinated controls operate in higher eukaryotes. [Supplemental Material]
Acknowledgments We thank Peter Devreotes and Rick Firtel for providing cell lines used in this study. We also thank Chris Janetopoulos for valuable discussions and for sharing unpublished observations. Finally, we thank members of the Parent laboratory as well as members of the laboratories of Alan Kimmel and Tian Jin for helpful discussions. This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research and by the National Institute of General Medical Sciences Pharmacology Research Associate program. Notes This article was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E05-08-0781) on November 2, 2005. Abbreviations used: ACA, adenylyl cyclase expressed during aggregation; CRAC, cytosolic regulator of adenylyl cyclase; GTPγS, guanosine 5′-3-O-(thio)triphosphate. The online version of this article contains supplemental material at MBC Online (http://www.molbiolcell.org).References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Trends Biochem Sci. 2001 Sep; 26(9):557-66.
[Trends Biochem Sci. 2001]Dev Cell. 2002 Oct; 3(4):469-78.
[Dev Cell. 2002]Curr Opin Cell Biol. 2002 Apr; 14(2):196-202.
[Curr Opin Cell Biol. 2002]Curr Opin Cell Biol. 2004 Feb; 16(1):4-13.
[Curr Opin Cell Biol. 2004]Proc Natl Acad Sci U S A. 1975 Dec; 72(12):4991-3.
[Proc Natl Acad Sci U S A. 1975]J Immunol. 1991 Jan 1; 146(1):224-32.
[J Immunol. 1991]J Leukoc Biol. 1994 Dec; 56(6):776-83.
[J Leukoc Biol. 1994]J Muscle Res Cell Motil. 2002; 23(7-8):793-802.
[J Muscle Res Cell Motil. 2002]IUBMB Life. 2004 Sep; 56(9):541-6.
[IUBMB Life. 2004]Cell. 1992 Apr 17; 69(2):305-15.
[Cell. 1992]J Cell Biol. 1994 Sep; 126(6):1537-45.
[J Cell Biol. 1994]J Cell Biol. 1995 Jun; 129(6):1659-65.
[J Cell Biol. 1995]Cell. 2002 May 31; 109(5):611-23.
[Cell. 2002]Curr Biol. 2005 Jan 26; 15(2):134-9.
[Curr Biol. 2005]Cell. 1998 Oct 2; 95(1):81-91.
[Cell. 1998]Genes Dev. 1997 Dec 1; 11(23):3218-31.
[Genes Dev. 1997]Curr Biol. 2004 Jul 27; 14(14):1296-302.
[Curr Biol. 2004]Mol Biol Cell. 1999 Sep; 10(9):2829-45.
[Mol Biol Cell. 1999]Mol Biol Cell. 2005 Oct; 16(10):4572-83.
[Mol Biol Cell. 2005]Dev Cell. 2005 Apr; 8(4):467-77.
[Dev Cell. 2005]Mol Cell Biol. 1995 Oct; 15(10):5645-56.
[Mol Cell Biol. 1995]J Cell Biol. 1997 Mar 24; 136(6):1271-86.
[J Cell Biol. 1997]Cell. 2002 May 31; 109(5):611-23.
[Cell. 2002]Methods Cell Biol. 1987; 28():299-331.
[Methods Cell Biol. 1987]Cell. 1998 Oct 2; 95(1):81-91.
[Cell. 1998]Cell. 1998 Oct 2; 95(1):81-91.
[Cell. 1998]J Immunol. 1975 Dec; 115(6):1650-6.
[J Immunol. 1975]Curr Biol. 2005 Jan 26; 15(2):134-9.
[Curr Biol. 2005]Cell. 1998 Oct 2; 95(1):81-91.
[Cell. 1998]J Biol Chem. 1995 Sep 29; 270(39):22693-6.
[J Biol Chem. 1995]Cell. 1998 Oct 2; 95(1):81-91.
[Cell. 1998]Adv Cyclic Nucleotide Res. 1979; 10():35-55.
[Adv Cyclic Nucleotide Res. 1979]Curr Biol. 2005 Jan 26; 15(2):134-9.
[Curr Biol. 2005]Dev Cell. 2005 Apr; 8(4):467-77.
[Dev Cell. 2005]Mol Biol Cell. 2003 May; 14(5):1913-22.
[Mol Biol Cell. 2003]Mol Cell Biol. 1995 Oct; 15(10):5645-56.
[Mol Cell Biol. 1995]J Cell Biol. 1997 Mar 24; 136(6):1271-86.
[J Cell Biol. 1997]J Cell Sci. 1998 Jan; 111 ( Pt 2)():283-94.
[J Cell Sci. 1998]J Cell Biol. 2001 May 14; 153(4):795-810.
[J Cell Biol. 2001]J Immunol. 1975 Dec; 115(6):1650-6.
[J Immunol. 1975]Curr Biol. 2005 Jan 26; 15(2):134-9.
[Curr Biol. 2005]Curr Biol. 2005 Jan 26; 15(2):134-9.
[Curr Biol. 2005]J Cell Biol. 2001 May 14; 153(4):795-810.
[J Cell Biol. 2001]EMBO J. 1999 Apr 15; 18(8):2092-105.
[EMBO J. 1999]Science. 2000 Feb 11; 287(5455):1037-40.
[Science. 2000]J Cell Sci. 1998 Jan; 111 ( Pt 2)():283-94.
[J Cell Sci. 1998]Cell. 1992 Apr 17; 69(2):305-15.
[Cell. 1992]Cell. 2003 Feb 21; 112(4):549-60.
[Cell. 2003]Cell. 2002 May 31; 109(5):611-23.
[Cell. 2002]Dev Cell. 2005 Apr; 8(4):467-77.
[Dev Cell. 2005]EMBO J. 1996 Oct 1; 15(19):5256-67.
[EMBO J. 1996]Cell. 2003 Feb 21; 112(4):549-60.
[Cell. 2003]Mol Biol Cell. 2003 May; 14(5):1913-22.
[Mol Biol Cell. 2003]J Cell Biol. 1979 Feb; 80(2):300-9.
[J Cell Biol. 1979]J Cell Biol. 1979 Aug; 82(2):517-27.
[J Cell Biol. 1979]J Cell Biol. 1999 Nov 1; 147(3):577-88.
[J Cell Biol. 1999]J Cell Biol. 1983 Jun; 96(6):1559-65.
[J Cell Biol. 1983]Genes Dev. 2004 Apr 1; 18(7):805-15.
[Genes Dev. 2004]Science. 1999 Apr 30; 284(5415):765-70.
[Science. 1999]Mol Cell Biol. 1993 Mar; 13(3):1657-65.
[Mol Cell Biol. 1993]EMBO J. 1994 Feb 1; 13(3):522-33.
[EMBO J. 1994]Nat Cell Biol. 2005 Aug; 7(8):785-96.
[Nat Cell Biol. 2005]Cell. 2002 May 31; 109(5):611-23.
[Cell. 2002]J Cell Biol. 2004 Nov 8; 167(3):505-18.
[J Cell Biol. 2004]Trends Genet. 2001 Jan; 17(1):41-8.
[Trends Genet. 2001]EMBO Rep. 2004 Jun; 5(6):602-6.
[EMBO Rep. 2004]Genome Biol. 2005; 6(8):R68.
[Genome Biol. 2005]Science. 2000 Feb 11; 287(5455):1049-53.
[Science. 2000]Science. 2000 Feb 11; 287(5455):1046-9.
[Science. 2000]Trends Biochem Sci. 2001 Sep; 26(9):557-66.
[Trends Biochem Sci. 2001]J Cell Biol. 2001 May 14; 153(4):795-810.
[J Cell Biol. 2001]Dev Cell. 2002 Oct; 3(4):469-78.
[Dev Cell. 2002]